Cellectis (CLLS) Profit After Tax (QoQ) (2015 - 2026)

Cellectis (CLLS) Profit After Tax (QoQ) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Cellectis 285.50 Mn 99.83 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 32.50%
Dec 31, 2025 -4,568.25%
Sep 30, 2025 102.48%
Jun 30, 2025 -30.94%
Mar 31, 2025 -406.11%
Dec 31, 2024 125.69%
Sep 30, 2024 8.76%
Jun 30, 2024 -547.81%
Mar 31, 2024 113.50%
Dec 31, 2023 -139.07%
Sep 30, 2023 -5.05%
Jun 30, 2023 48.84%
Mar 31, 2023 -13.89%
Dec 31, 2022 8.66%
Sep 30, 2022 -60.71%
Jun 30, 2022 44.03%
Mar 31, 2022 -23.78%
Dec 31, 2021 29.92%
Sep 30, 2021 3.70%
Jun 30, 2021 -171.15%